TGR5: Pathogenetic Role and/or Therapeutic Target in Fibrosing Cholangitis?

Clinical Reviews in Allergy and Immunology

Volumn 48, Issue 2-3, 2015, Pages 218-225

  Keitel, Verena ^a   Reich, Maria ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

AE2; Bicarbonate umbrella; Bile acids; CFTR; Choleresis; PSC

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

AGONISTS; ANIMAL; BILE DUCT; CELL TRANSFORMATION; CHOLANGITIS; CHOLESTASIS; COMPLICATION; EPITHELIUM CELL; FIBROSIS; GENETICS; HUMAN; IMMUNOLOGY; INTESTINE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; BILE DUCTS; CELL TRANSFORMATION, NEOPLASTIC; CHOLANGITIS; CHOLESTASIS; EPITHELIAL CELLS; FIBROSIS; HUMANS; INTESTINES; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84939815585     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-014-8443-x     Document Type: Review

References (77)

1. Karlsen TH, Schrumpf E, Boberg KM (2010) Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 24:655–666
2. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (2013) Primary sclerosing cholangitis. Lancet 382:1587–1599
3. Bowlus CL (2011) Cutting edge issues in primary sclerosing cholangitis. Clin Rev Allergy Immunol 41:139–150
4. Karlsen TH, Boberg KM (2013) Update on primary sclerosing cholangitis. J Hepatol 59:571–582
5. O'Mahony CA, Vierling JM (2006) Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 26:3–21
6. Chapman R, Cullen S (2008) Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol 14:3350–3359
7. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M (2011) Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 25:727–739
8. Worthington J, Cullen S, Chapman R (2005) Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 28:93–103
9. Ponsioen CY (2011) Novel developments in IBD-related sclerosing cholangitis. Best Pract Res Clin Gastroenterol 25(Suppl 1):S15–S18. doi:10.1016/S1521-6918:-1
10. Ponsioen CY, Kuiper H, ten Kate FJ, de van Milligen WM, van Deventer SJ, Tytgat GN (1999) Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 11:769–774
11. Seidel D, Eickmeier I, Kuhl AA, Hamann A, Loddenkemper C, Schott E (2014) CD8 T cells primed in the gut-associated lymphoid tissue induce immune-mediated cholangitis in mice. Hepatology 59:601–611
12. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M (2004) Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127:261–274
13. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, Neuberger J (2009) A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 15:330–340
14. Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L (2014) Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 40:3–15
15. Liaskou E, Jeffery LE, Trivedi PJ, Reynolds GM, Suresh S, Bruns T, Adams DH, Sansom DM, Hirschfield GM (2014) Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology 147(1):221–232
16. Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW, Corvera CU (2013) The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144:145–154
17. Ward JB, Mroz MS, Keely SJ (2013) The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. Neurogastroenterol Motil 25:708–711
18. Keitel V, Häussinger D (2013) TGR5 in cholangiocytes. Curr Opin Gastroenterol 29:299–304
19. Keitel V, Häussinger D (2012) Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 36:412–419
20. Keitel V, Häussinger D (2011) TGR5 in the biliary tree. Dig Dis 29:45–47
21. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S (2011) The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One 6:e25637
22. Pols TW, Nomura M, Harach T, Lo SG, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, Auwerx J, Schoonjans K (2011) TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14:747–757
23. Keitel V, Ullmer C, Häussinger D (2010) The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem 391:785–789
24. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Häussinger D (2009) The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50:861–870
25. Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D (2008) Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372:78–84
26. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278:9435–9440
27. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K (2002) Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298:714–719
28. Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R, Auwerx J (2008) Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 51:1831–1841
29. Wang YD, Chen WD, Yu D, Forman BM, Huang W (2011) The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54:1421–1432
30. Masyuk AI, Huang BQ, Radtke BN, Gajdos GB, Splinter PL, Masyuk TV, Gradilone SA, LaRusso NF (2013) Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol 304:G1013–G1024
31. Beuers U, Maroni L, Elferink RO (2012) The biliary HCO(3)(-) umbrella: experimental evidence revisited. Curr Opin Gastroenterol 28:253–257
32. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP (2010) The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52:1489–1496
33. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U (2012) A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55:173–183
34. Romero MF, Fulton CM, Boron WF (2004) The SLC4 family of HCO 3 - transporters. Pflugers Arch 447:495–509
35. Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, Oude Elferink RP, Prieto J, Medina JF (2008) Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 134:1482–1493
36. Melero S, Spirli C, Zsembery A, Medina JF, Joplin RE, Duner E, Zuin M, Neuberger JM, Prieto J, Strazzabosco M (2002) Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology 35:1513–1521
37. Strazzabosco M, Joplin R, Zsembery A, Wallace L, Spirli C, Fabris L, Granato A, Rossanese A, Poci C, Neuberger JM, Okolicsanyi L, Crepaldi G (1997) Na(+)-dependent and -independent Cl-/HCO-3 exchange mediate cellular HCO3- transport in cultured human intrahepatic bile duct cells. Hepatology 25:976–985
38. Uriarte I, Banales JM, Saez E, Arenas F, Oude Elferink RP, Prieto J, Medina JF (2010) Bicarbonate secretion of mouse cholangiocytes involves Na(+)-HCO(3)(-) cotransport in addition to Na(+)-independent Cl(-)/HCO(3)(-) exchange. Hepatology 51:891–902
39. Alpini G, Glaser S, Baiocchi L, Francis H, Xia X, LeSage G (2005) Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats. Hepatology 41:1037–1045
40. Howard M, Jiang X, Stolz DB, Hill WG, Johnson JA, Watkins SC, Frizzell RA, Bruton CM, Robbins PD, Weisz OA (2000) Forskolin-induced apical membrane insertion of virally expressed, epitope-tagged CFTR in polarized MDCK cells. Am J Physiol Cell Physiol 279:C375–C382
41. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, Mangelsdorf DJ (2011) The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 25:1066–1071
42. Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B, Sardella R, Pruzanski M, Roda A, Pastorini E, Schoonjans K, Auwerx J (2009) Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 52:7958–7961
43. Alpini G, Glaser S, Robertson W, Phinizy JL, Rodgers RE, Caligiuri A, LeSage G (1997) Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes. Am J Physiol 273:G518–G529
44. Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, Holcomb LA, Caligiuri A, LeSage GD (1999) Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology 116:179–186
45. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D, Kubitz R (2007) The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45:695–704
46. Reinehr R, Häussinger D (2004) Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 126:249–262
47. Keitel V, Reinehr R, Reich M, Sommerfeld A, Cupisti K, Knoefel WT, Häussinger D (2011) The membrane-bound bile acid receptor TGR5 (Gpbar-1) is highly expressed in intrahepatic cholangiocarcinoma (abstract). Hepatology 54:869
48. Haselow K, Bode JG, Wammers M, Ehlting C, Keitel V, Kleinebrecht L, Schupp AK, Häussinger D, Graf D (2013) Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol 94:1253–1264
49. Keitel V (2012) Bile acids as extrahepatic and interorgan signaling molecules. In: Häussinger D, Keitel V, Kubitz R (eds) Hepatobiliary transport in health and disease. DeGruyter Publishing, Berlin, pp 117–129
50. Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, Matsuoka K, Sato T, Koganei K, Sugita A, Kanai T, Hibi T (2013) TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology 139:19–29
51. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, Bunnett NW, Corvera CU (2010) Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 22:814–825
52. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177
53. Camilleri M, Vazquez-Roque MI, Carlson P, Burton D, Wong BS, Zinsmeister AR (2011) Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil 23:995–999, e458
54. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K (2011) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 54:1263–1272
55. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D, Murgolo NJ, Keane K, Davis HR Jr, Hedrick J, Gustafson EL (2006) Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 398:423–430
56. Vassileva G, Hu W, Hoos L, Tetzloff G, Yang S, Liu L, Kang L, Davis HR, Hedrick JA, Lan H, Kowalski T, Gustafson EL (2010) Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol 205:225–232
57. Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, Miyamoto Y, Kanatani A, Tamai Y (2006) Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 191:197–205
58. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40:1319–1323
59. Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismuller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S (2010) Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138:1102–1111
60. Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, ElSharawy A, Melum E, Boberg KM, Manke T, Balschun T, Schramm C, Bergquist A, Weismuller T, Gotthardt D, Rust C, Henckaerts L, Onnie CM, Weersma RK, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen CY, Wijmenga C, Vatn MH, Stokkers PC, Vermeire S, Mathew CG, Lie BA, Beuers U, Manns MP, Schreiber S, Schrumpf E, Häussinger D, Franke A, Karlsen TH (2010) Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 5:e12403
61. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36:321–327
62. Trauner M, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E (2012) Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment. Dig Dis 30(Suppl 1):39–47. doi:10.1159/000341123.:39-47
63. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G (1995) Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 36:268–273
64. Shukla VK, Tiwari SC, Roy SK (1993) Biliary bile acids in cholelithiasis and carcinoma of the gall bladder. Eur J Cancer Prev 2:155–160
65. Bernstein C, Holubec H, Bhattacharyya AK, Nguyen H, Payne CM, Zaitlin B, Bernstein H (2011) Carcinogenicity of deoxycholate, a secondary bile acid. Arch Toxicol 85:863–871
66. Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5–15
67. Blechacz B, Gores GJ (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48:308–321
68. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, Cevikbas F, Steinhoff M, Nassini R, Materazzi S, Guerrero-Alba R, Valdez-Morales E, Cottrell GS, Schoonjans K, Geppetti P, Vanner SJ, Bunnett NW, Corvera CU (2013) The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 123:1513–1530
69. Keitel V, Görg B, Bidmon HJ, Zemtsova I, Spomer L, Zilles K, Häussinger D (2010) The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 58:1794–1805
70. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology 51:660–678
71. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237–67
72. Van Nieuwkerk CM, Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, Offerhaus GJ (1996) Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111:165–171
73. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M (2011) Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO output. Hepatology 54:1303–1312
74. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Souza RF, Spechler SJ, Cao W (2010) Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 59:170–180
75. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M (2007) Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 354:154–159
76. Kubitz R, Wettstein M, Warskulat U, Häussinger D (1999) Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 116:401–410
77. Häussinger D, Reinehr R, Keitel V (2012) Bile acid signaling in the liver and the biliary tree. In: Häussinger D, Keitel V, Kubitz R (eds) Hepatobiliary transport in health and disease. DeGruyter Publishing, Berlin, pp 85–102